KADCYLA indications and patient eligibility

Indicated for second or later lines of therapy, or first-line use in select patient populations1

Indication
KADCYLA® (ado-trastuzumab emtansine), as a single agent, is indicated for the treatment of patients with HER2-positive (HER2+), metastatic breast cancer (MBC) who previously received trastuzumab and a taxane, separately or in combination. Patients should have either:

  • Received prior therapy for metastatic disease, or
  • Developed disease recurrence during or within six months of completing adjuvant therapy

In the Phase III EMILIA trial, most patients received KADCYLA as second or later line of therapy, with select patients treated first-line1*

*Patients (N=991) with HER2+, unresectable locally advanced or MBC were randomized to receive KADCYLA or lapatinib + capecitabine in the Phase III EMILIA trial. 12% of patients received KADCYLA in the first-line setting, 36% of patients received KADCYLA in the 2nd-line setting, and 52% received KADCYLA in the 3rd-line or later setting (based on systemic therapy in the metastatic setting).

  • Most patients (88%) had received one or more lines of systemic therapy in the metastatic setting

Prior trastuzumab and taxane received in the adjuvant or metastatic treatment setting. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.

NCCN=National Comprehensive Cancer Network.

How KADCYLA was studied

Find out more about the EMILIA clinical trial design.

KADCYLA survival data

Learn how KADCYLA performed in clinical trials vs lapatinib + capecitabine.

KADCYLA safety profile

Understand the adverse reactions.